CASE WESTERN RESERVE UNIVERSITY

NervGen Pharma has appointed Dr. Randall Kaye as Chief Medical Advisor to guide the clinical and regulatory strategy for NVG-291, following positive topline results from the chronic cohort of their Phase 1b/2a spinal cord injury trial.

Trailhead Biosystems has raised $20 million in funding led by MAK Capital to enhance its portfolio of induced pluripotent stem cell (iPSC) derived cells for research applications.

The American Heart Association has funded seven research projects with $1 million to identify which patients with obesity and cardiovascular disease benefit most from GLP-1/GIP medications.

University Hospitals and Case Western Reserve University launch an $8 million NIH-funded clinical trial to evaluate EsoCheck and EsoGuard technologies for detecting Barrett's Esophagus in non-GERD patients.

MedPacto partners with leading US institutions, including Stanford University and Case Western Reserve University, to conduct Phase 2 trial of vactosertib for pediatric osteosarcoma treatment.

A new study indicates that semaglutide, the active ingredient in Ozempic, may significantly reduce the risk of Alzheimer's disease in individuals with type 2 diabetes.

A new study suggests semaglutide, used for type 2 diabetes, may lower the risk of Alzheimer's disease compared to other diabetes medications.

Sacituzumab govitecan demonstrated a 41.9% overall response rate in patients with extensive-stage small cell lung cancer (ES-SCLC) who had progressed after one prior line of therapy.

Dr. Robert Salata, a distinguished figure in infectious disease research and education at University Hospitals and Case Western Reserve University, passed away on August 26 at the age of 72.

Breakthrough research reveals GLP-1 receptor agonists like Ozempic and Wegovy may reduce obesity-related cancer risk by 19% and bowel cancer risk by up to 50%, suggesting potential cancer prevention applications.